Is Chemerin Associated with Gestational Diabetes Mellitus? A Case-Control Study.
GDM
adipose
chemerin
placenta
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
04
2023
accepted:
20
07
2023
medline:
8
8
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
epublish
Résumé
The aim of this study was to investigate the relationship between gestational diabetes mellitus (GDM) and Chemerin by analyzing chemerin levels in peripheral blood and cord blood, and chemerin mRNA and its protein expression in placenta and adipose tissue. A case-control study was conducted in 110 women with GDM and 110 controls without GDM who received regular prenatal services and delivered at Shanghai Pudong New Area Healthcare Hospital for Women and Children from June 2019 to December 2020. The age, pre-pregnancy weight, pre-pregnancy BMI, antepartum BMI, TG/HDL ratio and TG levels in pregnant women with GDM were significantly higher than those in women without GDM, and HDL levels were significantly lower than those in the normal group. Chemerin in the umbilical cord blood of the GDM group was significantly higher than in that of the normal group, but there was no difference in chemerin levels in peripheral blood. In the two groups, the chemerin concentration in peripheral blood was significantly higher than that in umbilical cord blood (P<0.001). The Chemerin mRNA and protein expression levels in the placenta and adipose tissue of pregnant women in the GDM group were significantly higher than those in the normal group (P <0.001). In the GDM group, the expression of chemerin protein in adipose tissue was significantly higher than that in placental tissue. Regression analysis showed that the expression level of chemerin protein in placental tissue and adipose tissue was positively correlated with the risk of GDM. Elevated chemerin is closely related to the risk of GDM, and the placenta may be an important secretion of chemotactic factor sources in addition to adipose tissue and participate in the development of GDM.
Identifiants
pubmed: 37551337
doi: 10.2147/DMSO.S417632
pii: 417632
pmc: PMC10404406
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2271-2281Informations de copyright
© 2023 Ma et al.
Déclaration de conflit d'intérêts
All authors declare no conflicts of interest in this work.
Références
Caspian J Intern Med. 2018 Fall;9(4):368-375
pubmed: 30510652
Taiwan J Obstet Gynecol. 2021 Jul;60(4):695-699
pubmed: 34247809
Gene. 2018 Apr 5;649:87-92
pubmed: 29360607
Clin Endocrinol (Oxf). 2014 Jan;80(1):65-72
pubmed: 23286837
Diabet Med. 2014 Aug;31(8):936-40
pubmed: 24628007
Peptides. 2014 Dec;62:15-20
pubmed: 25278490
FASEB J. 2023 Mar;37(3):e22806
pubmed: 36786722
Front Endocrinol (Lausanne). 2016 Dec 12;7:157
pubmed: 28018292
Endocrinology. 2007 Oct;148(10):4687-94
pubmed: 17640997
Gynecol Endocrinol. 2019 Sep;35(9):737-751
pubmed: 30990092
Clin Endocrinol (Oxf). 2015 Jun;82(6):838-43
pubmed: 25640450
Exp Ther Med. 2020 Jan;19(1):710-716
pubmed: 31897106
J Obstet Gynaecol. 2018 May;38(4):482-487
pubmed: 29430984
Obesity (Silver Spring). 2017 Feb;25(2):468-475
pubmed: 28071854
Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):331-8
pubmed: 22119008
Peptides. 2018 Mar;101:157-166
pubmed: 29337272
Ann Endocrinol (Paris). 2015 Feb;76(1):19-24
pubmed: 25627894
Gynecol Endocrinol. 2020 Dec;36(12):1116-1118
pubmed: 32274942
Vascul Pharmacol. 2016 Feb;77:60-8
pubmed: 26304698
Scand J Gastroenterol. 2011 Jan;46(1):91-7
pubmed: 20809771
Med Arch. 2019 Jun;73(3):163-168
pubmed: 31404127
Lipids Health Dis. 2018 Jul 24;17(1):169
pubmed: 30041634
BMJ Open Diabetes Res Care. 2020 Jul;8(1):
pubmed: 32747382
Int J Mol Sci. 2021 Oct 27;22(21):
pubmed: 34769010
Medicine (Baltimore). 2019 Apr;98(16):e15320
pubmed: 31008986
J Diabetes. 2018 Jun;10(6):487-495
pubmed: 28436169
Adv Exp Med Biol. 2017;960:277-304
pubmed: 28585204